Almost a year after Neurochem Inc. received its first approvable letter for Kiacta (eprodisate) in the treatment of AA amyloidosis, history repeated itself. (BioWorld Today)
Almost a year after Neurochem Inc. received its first approvable letter for Kiacta (eprodisate) in the treatment of AA amyloidosis, history repeated itself. (BioWorld Today)
Metabasis Therapeutics Inc. lost more than half its value on Tuesday after announcing that CS-917, the lead candidate in its metabolic disease program, failed a Phase IIb diabetes trial, while pradefovir, the lead candidate in its liver disease program, was dropped by partner Schering-Plough Corp. (BioWorld Today)
